EFERMIA Trademark

Trademark Overview


On Thursday, May 16, 2019, a trademark application was filed for EFERMIA with the United States Patent and Trademark Office. The USPTO has given the EFERMIA trademark a serial number of 79261532. The federal status of this trademark filing is IR CANCELLED - US REGISTRATION CANCELLED as of Thursday, March 26, 2020. This trademark is owned by Glaxo Group Limited. The EFERMIA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines * ; none of the aforesaid goods acting on the central nervous system *
efermia

General Information


Serial Number79261532
Word MarkEFERMIA
Filing DateThursday, May 16, 2019
Status404 - IR CANCELLED - US REGISTRATION CANCELLED
Status DateThursday, March 26, 2020
Registration Number5964213
Registration DateTuesday, January 21, 2020
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 5, 2019

Trademark Statements


Certificate of Correction for RegistrationIn the statement, "International Class 5 " is corrected per the Restriction and the fnote dated 1/21/2020
Goods and ServicesPharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines * ; none of the aforesaid goods acting on the central nervous system *

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeH - NOT AVAILABLE
Class Status DateThursday, March 26, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameGlaxo Group Limited
Party Type30 - Original Registrant
Legal Entity Type11 - Company
AddressGB

Party NameGlaxo Group Limited
Party Type20 - Owner at Publication
Legal Entity Type11 - Company
AddressGB

Party NameGlaxo Group Limited
Party Type10 - Original Applicant
Legal Entity Type11 - Company
AddressGB

Trademark Events


Event DateEvent Description
Sunday, April 12, 2020NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Friday, April 10, 2020NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED
Thursday, April 9, 2020DEATH OF INTERNATIONAL REGISTRATION
Tuesday, March 17, 2020LIMITATION FROM THE IB EXAMINED AND ENTERED
Tuesday, March 17, 2020CORRECTION UNDER SECTION 7 ¿ PROCESSED
Tuesday, March 17, 2020CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Tuesday, January 21, 2020REGISTERED-PRINCIPAL REGISTER
Friday, November 22, 2019LIMITATION OF GOODS RECEIVED FROM IB
Tuesday, November 5, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 5, 2019PUBLISHED FOR OPPOSITION
Saturday, November 2, 2019NOTIFICATION PROCESSED BY IB
Wednesday, October 16, 2019NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, October 16, 2019NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, October 16, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, September 30, 2019ASSIGNED TO LIE
Tuesday, September 24, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, September 23, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, September 23, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, September 23, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, August 16, 2019REFUSAL PROCESSED BY IB
Saturday, July 27, 2019NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Saturday, July 27, 2019REFUSAL PROCESSED BY MPU
Saturday, July 6, 2019NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Friday, July 5, 2019NON-FINAL ACTION WRITTEN
Thursday, July 4, 2019ASSIGNED TO EXAMINER
Tuesday, July 2, 2019APPLICATION FILING RECEIPT MAILED
Friday, June 28, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, June 27, 2019SN ASSIGNED FOR SECT 66A APPL FROM IB